Ligand validation:4I22

IRE: Gefitinib

IRE is a Ligand Of Interest in 4I22 designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
4I22_IRE_A_9001	85%	28%	0.104	0.968	1.75	1.18	9	2	1	0	100%	1
4WKQ_IRE_A_1101	44%	17%	0.163	0.89	1.63	2.01	6	10	1	0	100%	1
3UG2_IRE_A_1	29%	15%	0.24	0.898	1.24	2.46	4	17	2	0	100%	0.5
2ITZ_IRE_A_2021	21%	22%	0.254	0.863	1.39	1.85	2	12	3	0	100%	1
2ITO_IRE_A_2020	6%	22%	0.347	0.791	1.34	1.88	3	10	3	0	100%	1
2ITY_IRE_A_2020	6%	19%	0.34	0.782	1.75	1.7	4	10	5	0	100%	1
5Y80_IRE_A_401	45%	11%	0.184	0.917	1.73	2.45	10	18	2	0	100%	1
5Y7Z_IRE_A_401	36%	10%	0.226	0.919	1.82	2.46	10	17	1	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.